BT7480

Phase 2

BICYCLE THERAPEUTICS PLC (BCYC)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Development History

Aug '26

BCYCPhase 2$120M

✓Completed

Nivolumab Phase 2 Est. Readout

BT7480• Advanced Solid Tumor200

Aug 2026~Confirmed

CT.gov

Competitive Landscape

6 competitors in Advanced Solid Tumor

Drug Information

Target Indication

Advanced Solid Tumor

Clinical Trial

NCT05163041

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BCYC

BICYCLE THERAPEUTICS PLC

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

BT8009Phase 3

Urinary Bladder Neoplasm

Gemcitabine + cisplatin Or carboplatinPhase 3

Metastatic Urothelial Cancer

Zelenectide pevedotin (BT8009)Phase 2

Non-Small Cell Lung Cancer

BT5528Phase 2

Advanced Solid Tumor Historically Known for High EphA2 Expression

nuzefatide pevedotin (BT5528)Phase 2

Pancreatic Ductal Adenocarcinoma (PDAC)

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts